We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Congrès Targeted Anticancer Therapies - TAT 2014.
- Authors
Bellesoeur, A.; Brunot, A.; Calcagno, F.; Grellety, T.; Loirat, D.; Tabouret, E.; Tlemsani, C.; Sajous, C.; Vicier, C.; Rousseau, B.; Soria, J.
- Abstract
Major innovations about targeted anticancer therapies were discussed during the TAT 2014 congress, in Washington, March 5-7, 2014. Dr Patricia M. LoRusso (Detroit), one of the most productive oncology phase 1 investigators, introduced the congress with her speech about 'The Changing Landscape of Early Phase Trials.' Then, various presentations on a broad range of new promising targeted cancer therapeutics and their development issues confirmed this idea. As a major topic, immunotherapy began the congress, wondering about the role of Programmed Death Ligand 1 (PDL1) as efficacy biomarker and possibilities of immunologic agents association. Among the promising molecules, the congress presented inhibitors of cdk4/6 as cell cycle targets and FGFR inhibitors with their major challenge of identifying accessible response biomarker. Special sessions were devoted to methodological evolutions such as preclinical models development, circulating tumoral DNA, or the role of genomics in early-phase drug development. The French basket trial SHIVA was presented to illustrate the place of genomics in newly conceived trials. SHIVA is a phase II trial evaluating efficacy and feasibility of a targeted treatment according to the molecular profile versus standard treatment. Finally, methodological issues in early drug development were discussed with biomarker's challenge, correlating signaling inhibition and drug resistance to targeted agents.
- Publication
Oncologie (Tech Science Press), 2014, Vol 16, Issue 7/8, p367
- ISSN
1292-3818
- Publication type
Report
- DOI
10.1007/s10269-014-2416-9